Roughly four in ten older adults worldwide take five or more medications daily, a threshold commonly used to define polypharmacy. In parts of Europe and among hospitalized or frail populations, the proportion is even higher. While every one of those prescriptions may have been reasonable on its own, the combination creates risks that climb steeply with each added drug: adverse reactions, emergency visits, falls, cognitive fog, and healthcare costs that can nearly double. The good news is that a growing body of evidence shows many of these medications can be safely reduced or stopped, and most older adults are open to the idea.
How Common Polypharmacy Really Is
The most common definition of polypharmacy is the concurrent use of five or more medications. “Hyperpolypharmacy” or “excessive polypharmacy” typically means ten or more. A 2024 systematic review and meta-analysis covering elderly populations worldwide estimated an overall polypharmacy prevalence of about 39%, with hyperpolypharmacy at roughly 13%.1PubMed. Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta-Analysis Europe showed the highest regional rate at around 46%, followed by Oceania and North America, with Asia and South America somewhat lower.
Those numbers shift dramatically depending on the clinical setting. A separate umbrella review covering nearly 60 million participants found that while the general older population sits around 45%, outpatients reach 48%, inpatients 52%, and frail elderly individuals 59%. Among frail older adults in hospital settings, the figure climbs to 71%.2PubMed. Global and regional prevalence of polypharmacy and related factors, 1997-2022: An umbrella review In other words, the sicker and more institutionalized the population, the more pills accumulate. This makes intuitive sense: someone with heart disease, diabetes, arthritis, and depression will end up on medications from four different specialists, each prescribing according to their own disease-specific guideline.
Why Aging Bodies Handle Drugs Differently
Polypharmacy would be less dangerous if older bodies processed medications the same way younger ones do. They don’t. As people age, the kidneys gradually lose filtering capacity and the liver becomes less efficient at breaking down certain compounds. Fat-soluble drugs get stored in a larger reservoir of body fat while lean muscle and total body water decrease, meaning the same dose can produce higher concentrations in the bloodstream for longer periods.3PubMed Central. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review
On top of slower clearance, older adults tend to be more sensitive to the effects of many drug classes. Anticoagulants, blood-sugar-lowering medications, and drugs that act on the brain all tend to hit harder.4PubMed Central. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications The cardiovascular and central nervous systems seem to be particularly affected.5PubMed. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications So the problem is not just too many pills; it is too many pills in a body that absorbs them differently, clears them more slowly, and reacts to them more intensely.
Adverse Drug Reactions and Emergency Visits
The most immediate danger of polypharmacy is the adverse drug reaction. One emergency department study found that adverse drug-related events accounted for about 11% of all ED visits by older adults, with patients taking an average of just over four medications each.6Annals of Emergency Medicine. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department That is roughly one in nine visits triggered by a medication problem rather than a new illness.
Being over 65, taking more than five drugs, and recently starting a high-risk medication have all been identified as key risk factors for hospital admissions tied to adverse drug events.7PubMed. Risk factors for hospital admissions associated with adverse drug events The risk is not uniform across all medication combinations, however. A large primary-care study of adults aged 65 to 100 found enormous variability in risk depending on which specific drugs were combined: patients in the highest-risk group of medication combinations had roughly seven times the odds of an adverse-drug-reaction-related hospital admission compared with those in the lowest-risk group.8PLoS ONE. Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions The particular mix matters as much as the raw count.
The Prescribing Cascade Trap
One of the most insidious ways medication lists grow is the prescribing cascade. This happens when a side effect from one drug gets mistaken for a new medical condition, prompting another prescription to treat it.9PubMed Central. Prescribing Cascades: How to Detect Them, Prevent Them, and Use Them Appropriately A classic example: a calcium channel blocker causes ankle swelling, which gets diagnosed as edema, which leads to a diuretic prescription, which lowers potassium, which leads to a potassium supplement. A single side effect has spawned two extra drugs.
These cascades are surprisingly common in hospitalized older adults.10PubMed. Prescribing cascades among hospitalized older adults: a retrospective cohort study from the REPOSI registry They are hard to spot in real time because each new prescription seems justified when viewed in isolation. The problem only becomes visible when someone steps back and asks: did this symptom exist before the earlier drug was started? Recognizing and interrupting prescribing cascades is one of the highest-leverage things a clinician or pharmacist can do to trim unnecessary medications.
Falls, Fractures, and Mobility
Falls are the leading cause of injury-related death in older adults, and medications play a larger role than many people realize. Several drug classes are formally classified as “fall-risk-increasing drugs,” including opioids, antidepressants, sedatives, anxiolytics, and dopamine-related agents. Use of these drugs is associated with a higher risk of hip fracture even after adjusting for the chronic conditions that prompted the prescriptions in the first place.11PubMed Central. Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: a cohort study
The risk compounds when multiple fall-risk-increasing drugs are combined. A population-based study found a dose-response pattern: the more of these drugs taken together, the higher the fracture risk, with the absolute danger being greatest in people 75 and older. Some individual drug classes carried strikingly high absolute risk in that age group. SSRIs, tricyclic antidepressants, and antipsychotics each had a number needed to harm under 100, meaning that for every 53 to 81 older adults prescribed these drugs, one additional fracture could be expected.12Age and Ageing. Single and combined use of fall-risk-increasing drugs and fracture risk: a population-based case–control study For someone already at risk of a broken hip, those are not small numbers.
Effects on Thinking and Memory
There is growing concern that polypharmacy contributes to cognitive decline, though disentangling the effect of the medications from the effect of the diseases they treat is genuinely difficult. A Taiwanese survey found that polypharmacy was associated with about 1.75 times the odds of mild cognitive impairment and 2.33 times the odds of dementia after adjusting for age, sex, education, and medical conditions.13PubMed. Association of Polypharmacy With Mild Cognitive Impairment and Cognitive Ability: A Nationwide Survey in Taiwan
However, the picture gets murkier with closer scrutiny. A three-year European study initially found that polypharmacy was linked to higher odds of mild cognitive impairment, but the association faded to nonsignificance once mental health conditions and multimorbidity were fully accounted for.14Journal of the American Medical Directors Association. Association of Polypharmacy With Mild Cognitive Impairment in Community-Dwelling Older Adults: A 3-Year Prospective Analysis of the DO-HEALTH Study That suggests at least some of the apparent cognitive harm attributed to polypharmacy may really stem from the burden of having multiple chronic diseases.
Anticholinergic drugs deserve special mention. These are medications with properties that block the neurotransmitter acetylcholine, and they turn up in surprising places: certain antihistamines, bladder medications, older antidepressants, and some over-the-counter sleep aids. Higher cumulative anticholinergic exposure has been linked to poorer cognitive and functional outcomes in cohort studies.15PubMed Central. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review A UK Biobank simulation study found that the effect sizes of anticholinergic drug scales on dementia risk overlapped substantially with the effect sizes of general polypharmacy scales, though anticholinergic scales showed somewhat larger average effects.16The Journals of Gerontology: Series A. A simulation study comparing anticholinergic drug use with polypharmacy for risk of death, dementia, and delirium in UK Biobank The practical takeaway: if you are concerned about protecting cognitive function, reviewing anticholinergic medications is a good place to start.
When Guidelines Themselves Drive the Problem
Here is the uncomfortable paradox at the heart of polypharmacy: most of those medications were prescribed in good faith, following evidence-based guidelines. The trouble is that clinical guidelines are overwhelmingly written for single diseases. If you follow the guideline for hypertension, the guideline for diabetes, the guideline for osteoporosis, and the guideline for depression, you can easily end up with eight to twelve medications, all individually “appropriate.” A systematic review of guideline quality found that the complexity and variability of patients with multiple chronic conditions renders traditional disease-focused guidelines often inadequate.17PubMed. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus
This problem has not escaped the people who write guidelines. The Guidelines International Network’s Multimorbidity Working Group has argued for a decade that single-disease guidelines contribute to “too much medicine,” including an abundance of diagnostic and treatment measures that can potentially harm the patient.18PubMed Central. Is ‘too much medicine’ a guideline-driven phenomenon? Ten years’ report and reflections of the Guidelines International Network Multimorbidity Working Group Change has been slow, though. Most clinical decision-making still proceeds one disease at a time.
Screening Tools and How They Work
Several structured tools exist to flag potentially inappropriate prescriptions. The two most widely used internationally are the Beers Criteria, developed primarily in the United States, and the STOPP/START criteria, developed in Europe. Both aim to identify medications that are risky for older adults (drugs to stop) and beneficial treatments that are being omitted (drugs to start). In a study at a tertiary care center in India, applying these criteria led to recommendations for modifying over 200 medications, with actual changes implemented in about 28% of cases using Beers criteria and about 49% using STOPP/START criteria.19PubMed Central. Usefulness of STOPP/START criteria and Beers criteria for prescribing in geriatric patients in a tertiary health care center, Raipur, Central India Those gaps between “recommended” and “implemented” hint at how hard it is to change prescribing habits in practice, even when the evidence is clear.
How Deprescribing Works
Deprescribing is the planned, supervised process of reducing or stopping medications that are no longer needed or whose risks now outweigh their benefits. It is not the same as abruptly dropping pills. A structured approach with tapering, monitoring, and follow-up can minimize or prevent the rebound effects and withdrawal symptoms that sometimes occur when medications are stopped suddenly.20PubMed. Deprescribing in older adults
Tapering schedules vary by drug class. For medications like benzodiazepines, antidepressants, or beta-blockers, gradual reduction over four to six weeks is generally recommended to avoid withdrawal. For others, the evidence suggests that stopping abruptly is safe. Peripheral alpha-blockers used for prostate symptoms, for instance, can be discontinued without the rebound hypertension that was historically feared.21PubMed Central. Avoiding Adverse Drug Withdrawal Events When Stopping Unnecessary Medications According to the STOPPFrail Criteria The key is matching the withdrawal strategy to the specific drug’s pharmacology.
Encouragingly, the vast majority of patients are on board with the idea. A systematic review and meta-analysis found that about 88% of patients were willing to deprescribe if their doctor suggested it. Caregivers were somewhat more cautious, with about 75% willing. Willingness did not vary by location, study population, or number of medications taken.22PubMed Central. How Willing Are Patients or Their Caregivers to Deprescribe: a Systematic Review and Meta-analysis The barrier, it seems, is less about patient resistance and more about clinician inertia and the lack of systems to support the process.
The Role of Pharmacist-Led Reviews
Pharmacists are increasingly recognized as central players in managing polypharmacy. A broad review of pharmacist interventions found that they have the potential to reduce the number of medications and doses, improve adherence, prevent adverse reactions, and lower both drug costs and facility costs.23PubMed Central. The effects of pharmacist interventions on patients with polypharmacy In a controlled study, pharmacist-led comprehensive medication reviews cut the number of medication-related problems by more than half compared with a control group.24PubMed Central. Impact of Pharmacist-Conducted Comprehensive Medication Reviews for Older Adult Patients to Reduce Medication Related Problems
A meta-analysis of randomized controlled trials specifically looking at community pharmacists found that their medication reviews reduced the risk of emergency department visits by about a third compared with usual care. There was also a trend toward fewer hospitalizations, though that result did not quite reach statistical significance.25Journal of Patient Safety. Impact of Medication Reviews Delivered by Community Pharmacist to Elderly Patients on Polypharmacy: A Meta-analysis of Randomized Controlled Trials If you or a family member takes five or more medications, asking for a comprehensive medication review from a pharmacist is one of the most practical steps available.
What Happens During Hospital Transitions
Hospital stays are a particularly hazardous time for medication accumulation. A study of over 2,100 patients found that 45% were on five or more drugs before hospitalization. Within 90 days of discharge, that figure jumped to 74% and remained above 70% a full year later. During those first 90 days, patients started an average of 3.3 new medications, and 80% started at least one new drug. At the same time, 74% stopped at least one medication, meaning the churn was enormous: drugs being added and dropped at high rates, with the net effect being significantly more pills than before.26PubMed Central. Medication transitions and polypharmacy in older adults following acute care
This transition period is dangerous because communication between hospital doctors, primary care physicians, and patients often breaks down. The hospital team may have started a proton pump inhibitor to protect the stomach during a stressful admission, an anti-nausea drug that was only needed post-surgery, or a sleeping pill that made sense in a noisy ward. Without a deliberate review at discharge and again a few weeks later, those short-term medications become permanent fixtures on the pill list. Anyone leaving the hospital on new medications should ask: which of these are meant to be temporary, and when should I stop them?
The Financial Toll
Polypharmacy does not just cost health; it costs money. Two recent U.S. studies using propensity-matched designs converged on strikingly similar figures: polypharmacy was associated with roughly $4,300 more in total annual healthcare spending per person, driven by higher costs for office visits, outpatient care, inpatient stays, and the prescription drugs themselves.27PubMed Central. Polypharmacy and healthcare expenditures among older adults in the United States: a propensity score-matched study Most of the extra expense fell on Medicare and private insurance, but patients themselves faced about $589 more in out-of-pocket costs.28Value in Health. Quantifying the Impact of Polypharmacy on Healthcare Expenditure in Older Adults
Perhaps more troubling, polypharmacy was associated with roughly 70% to 90% higher odds of cost-related nonadherence, meaning people skip doses or split pills because they cannot afford all their medications.27PubMed Central. Polypharmacy and healthcare expenditures among older adults in the United States: a propensity score-matched study This creates a vicious feedback loop: more drugs, higher costs, more skipping, worse outcomes, more emergency visits, more drugs.
Socioeconomic Disparities
Polypharmacy does not hit everyone equally. A systematic review and meta-analysis found that people with lower educational backgrounds had about 21% higher odds of being on five or more medications, with similar patterns for lower income, lower occupational status, and lower social class.29PubMed Central. Are there socioeconomic inequalities in polypharmacy among older people? A systematic review and meta-analysis This likely reflects the higher burden of chronic disease in disadvantaged populations, along with potential differences in access to the kind of proactive medication reviews that catch unnecessary prescriptions.
Interestingly, a 14-country study found that older adults with lower socioeconomic status were actually more willing to have medications deprescribed, but they also reported lower satisfaction with their current medications, worse self-rated health, and substantially lower health literacy.30PubMed Central. Association between older adults’ socioeconomic status and their healthcare experiences, preferences, and attitudes towards deprescribing: a cross-sectional study in 14 countries Lower health literacy makes it harder to navigate conversations about medication changes, advocate for yourself in appointments, or recognize when a symptom might be a side effect rather than a new disease. Addressing polypharmacy effectively in these populations requires more than just better prescribing. It requires accessible communication, longer appointments, and proactive outreach.
Drug Interaction Alerts and Why Technology Has Not Solved This Yet
Electronic prescribing systems routinely generate drug-drug interaction alerts, and you might assume these would make a significant dent in the problem. The evidence is disappointing. A systematic review of studies evaluating these alert systems found that they did not lead to significant reductions in potentially adverse drug-drug interactions overall, and the results varied enormously from study to study.31Journal of the American Medical Informatics Association. Effect of electronic drug-drug interaction alerts on patient and clinician outcomes: a systematic review The main culprit seems to be alert fatigue: when prescribers are bombarded with warnings for clinically trivial interactions, they learn to click past all of them, including the ones that matter. Smarter systems that prioritize truly dangerous combinations over minor ones are an active area of development, but we are not there yet.
Deprescribing at the End of Life
One area where deprescribing seems most clearly beneficial, yet happens least, is in patients nearing the end of life. Preventive medications like statins, blood pressure drugs, and antiplatelet agents were designed to reduce risks years into the future. When someone’s life expectancy is measured in months, those long-term benefits evaporate while the daily burden of side effects, swallowing difficulties, and cost persists. Evidence supports the safety of stopping certain preventive medications in palliative settings.32PubMed Central. Deprescribing in palliative care A systematic review of discontinuation in patients with limited life expectancy found that statins, warfarin, and aspirin were the most commonly stopped preventive drugs, though some patients continued taking them right until death.33PubMed. Discontinuation of Preventive Medicines in Older People with Limited Life Expectancy: A Systematic Review
A recent UK study looking at the last 12 months of life in palliative care patients found that actual deprescribing of preventive medications occurred in only a very small number of patients, with the most common changes involving blood pressure drugs and antiplatelets.34PubMed. Deprescribing of preventive medications in palliative care patients living with multiple long-term conditions in their final 12 months of life The reluctance seems to come from all directions: patients worry about “giving up,” families fear that stopping a medication signals abandonment, and clinicians hesitate to change what a colleague prescribed. Having explicit conversations about treatment goals as health declines can open the door to a lighter, more comfortable medication regimen.
Non-Drug Alternatives for Common Complaints
One overlooked route to fewer medications is replacing a drug with a non-drug intervention. This is most practical for conditions where behavioral or lifestyle approaches have good evidence. Insomnia is a prime example: cognitive behavioral therapy for insomnia is recommended as a first-line treatment ahead of sleeping pills in older adults, yet prescribing a sedative is far easier in a 10-minute appointment. Research into what helps clinicians make the switch has found that patients’ willingness to try alternatives and having printed information ready to hand out during consultations are among the strongest enabling factors.35PubMed. Managing insomnia in the elderly – what prevents us using non-drug options? Exercise programs for mild hypertension, physical therapy for chronic pain, and dietary changes for early-stage type 2 diabetes are other places where a non-pharmacological approach can reduce the pill count without compromising outcomes. These substitutions work best when the patient, the prescriber, and sometimes a pharmacist are all part of the conversation.